Lysophospholipid Signaling Molecules in Fundus Neovascular Diseases
International Journal of Molecular Sciences · 09.11.2026 · 27 (21) · 10025
DOI: 10.3390/ijms272110025 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 09.11.2026. Verfasst von Xinbei Zhou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Joint Shantou International Eye Center of Shantou University and The Chinese University of Hong Kong, Shantou 515041, China. Hauptthemen laut MEDLINE: Lysophospholipids, Signal Transduction, Neovascularization, Pathologic. Die Arbeit nennt 145 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Special Projects in Key Fields of Colleges and Universities in Guangdong Province, Guangdong Basic and Applied Basic Research Foundation, Shantou Medical Health, Science and Technology Project Foundation.
Abstract (Originalsprache)
Fundus neovascular diseases (FNDs) are vision-threatening ocular disorders featuring pathological neovascularization and pose a major global threat to vision health. Their pathogenesis is heterogeneous, involving multiple factors and pathways. Current clinical pharmacotherapies only target a limited range of molecular pathways via narrow mechanisms, leading to frequent suboptimal responses and disease recurrence, which restricts further therapeutic improvement for FNDs. Recent studies demonstrate that lysophospholipid signaling molecules selectively activate multiple cell-surface receptors, including G protein-coupled receptors, triggering multilayered downstream signaling cascades that govern neovascular initiation and progression. Aberrant activation of this endogenous signaling axis may underpin the limited efficacy of existing anti-angiogenic therapies, and its roles in pathological neovascularization have attracted intensive research attention. This review addresses three representative lysophospholipid mediators: lysophosphatidic acid, lysophosphatidylcholine, and sphingosine-1-phosphate. We systematically summarize their metabolic routes, receptor binding profiles, downstream signaling networks, and pro-angiogenic mechanisms. We also discuss the current research status and translational potential of targeting lysophospholipid axes as innovative therapies, aiming to provide theoretical and translational evidence for developing precise pathway-directed interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Joint Shantou International Eye Center of Shantou University and The Chinese University of Hong Kong, Shantou 515041, China.
- Fifth Clinical Institute of Shantou University Medical College, Shantou 515041, China.
- Department of Ophthalmology & Visual Sciences, The Chinese University of Hong Kong, Hong Kong SAR 999077, China.
ORCID-Profile: Wai Kit Chu, Changzhen Fu
Förderung
- Special Projects in Key Fields of Colleges and Universities in Guangdong Province
- Guangdong Basic and Applied Basic Research Foundation
- Shantou Medical Health, Science and Technology Project Foundation
- Shantou University Medical College Research Incubation Program
- Key Research Platforms and Projects of Guangdong Provincial Universities
- Guangdong Basic and Applied Basic Research Fund Provincial Enterprise Joint Fund
Zitieren
APA
Zhou, X., Chen, S., Liang, J., Chen, J., Hu, H., Chu, W. K., Liu, Q., & Fu, C. (2026). Lysophospholipid Signaling Molecules in Fundus Neovascular Diseases. International Journal of Molecular Sciences, 27(21), 10025. https://doi.org/10.3390/ijms272110025
Vancouver
Zhou X, Chen S, Liang J, Chen J, Hu H, Chu WK, et al. Lysophospholipid Signaling Molecules in Fundus Neovascular Diseases. International Journal of Molecular Sciences. 2026;27(21):10025. doi:10.3390/ijms272110025
BibTeX
@article{Zhou2026,
author = {Zhou, Xinbei and Chen, Shaolang and Liang, Jiajian and Chen, Junchao and Hu, Hongan and Chu, Wai Kit and Liu, Qingping and Fu, Changzhen},
title = {Lysophospholipid Signaling Molecules in Fundus Neovascular Diseases},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {21},
pages = {10025},
doi = {10.3390/ijms272110025}
}
EUVIMED